History & Locations
Glaukos milestone achievements
Glaukos founded and incorporated.
The first human implant of Glaukos micro-bypass glaucoma stent is performed. Glaukos Corporation commences operations.
In consultation with, and with the approval of the American Academy of Ophthalmology (AAO), Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the trabecular meshwork.
iStent is approved by FDA for insertion in combination with cataract surgery and becomes the first MIGS device commercially available in the United States. [Important Safety Information]
Glaukos establishes direct sales organisation and launches iStent inject® in Germany.
iStent approved in Japan. Glaukos establishes direct sales organisation and launches iStent inject in Australia and Canada. New Glaukos headquarters is established in San Clemente, California.
Glaukos commences U.S. launch of iStent inject following FDA approval for use in combination with cataract surgery. [Important Safety Information] Glaukos commences Phase III IND clinical trials for iDose Travoprost. Glaukos commences an FDA clinical trial for iStent infinite. Glaukos enters pharmaceutical development agreement with D. Western Therapeutics Institute, Inc., preeminent research organisation for proprietary Rho Kinase Inhibitor compounds.
Glaukos produces first model of micro-bypass glaucoma stent.
Glaukos commences U.S. IDE clinical trial to evaluate iStent® in conjunction with cataract surgery; this landmark trial is the first of its kind ever conducted in support of a glaucoma device.
In consultation with, and with the approval of the AAO, Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the suprachoroidal space.
100% Medicare coverage for iStent procedure is secured.
Glaukos completes patient enrollment of U.S. IDE pivotal trial to evaluate iStent inject in combination with cataract surgery. Glaukos completes initial public offering and common stock begins trading on New York Stock Exchange under ticker GKOS.
Glaukos global direct sales operations expands to 17 countries and more than 170 professionals. iStent inject is approved in Brazil, Israel, Malaysia, Saudi Arabia, and Singapore. Glaukos completes Phase II IND clinical trial for iDose Travoprost. Glaukos acquires early-stage intraocular pressure sensor system assets to complement its micro-scale surgical and drug delivery technology platforms.
Total number of iStent devices implanted exceeds 500,000. Glaukos enters the corneal health market with the acquisition of Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. Glaukos concludes patient enrollment of the clinical trial for iStent infinite. Glaukos announces the collaboration and distribution agreement with Santen for exclusive distribution of the MicroShunt (DE-128) for patients with refractory glaucoma in the United States. Glaukos announces agreement with Intratus, Inc., to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.
Glaukos founded and incorporated.
Glaukos produces first model of micro-bypass glaucoma stent.
The first human implant of Glaukos micro-bypass glaucoma stent is performed. Glaukos Corporation commences operations.
Glaukos commences U.S. IDE clinical trial to evaluate iStent® in conjunction with cataract surgery; this landmark trial is the first of its kind ever conducted in support of a glaucoma device.
In consultation with, and with the approval of the American Academy of Ophthalmology (AAO), Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the trabecular meshwork.
In consultation with, and with the approval of the AAO, Glaukos applies for and received a Category III CPT code to describe insertion of a flow device into the suprachoroidal space.
iStent is approved by FDA for insertion in combination with cataract surgery and becomes the first MIGS device commercially available in the United States. [Important Safety Information]
100% Medicare coverage for iStent procedure is secured.
Glaukos establishes direct sales organisation and launches iStent inject® in Germany.
Glaukos completes patient enrollment of U.S. IDE pivotal trial to evaluate iStent inject in combination with cataract surgery. Glaukos completes initial public offering and common stock begins trading on New York Stock Exchange under ticker GKOS.
iStent approved in Japan. Glaukos establishes direct sales organisation and launches iStent inject in Australia and Canada. New Glaukos headquarters is established in San Clemente, California.
Glaukos global direct sales operations expands to 17 countries and more than 170 professionals. iStent inject is approved in Brazil, Israel, Malaysia, Saudi Arabia, and Singapore. Glaukos completes Phase II IND clinical trial for iDose Travoprost. Glaukos acquires early-stage intraocular pressure sensor system assets to complement its micro-scale surgical and drug delivery technology platforms.
Glaukos commences U.S. launch of iStent inject following FDA approval for use in combination with cataract surgery. [Important Safety Information] Glaukos commences Phase III IND clinical trials for iDose Travoprost. Glaukos commences an FDA clinical trial for iStent infinite. Glaukos enters pharmaceutical development agreement with D. Western Therapeutics Institute, Inc., preeminent research organisation for proprietary Rho Kinase Inhibitor compounds.
Total number of iStent devices implanted exceeds 500,000. Glaukos enters the corneal health market with the acquisition of Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. Glaukos concludes patient enrollment of the clinical trial for iStent infinite. Glaukos announces the collaboration and distribution agreement with Santen for exclusive distribution of the MicroShunt (DE-128) for patients with refractory glaucoma in the United States. Glaukos announces agreement with Intratus, Inc., to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.
Empowering ophthalmic
growth worldwide
With direct sales operations in 17 countries, we employ more than 200 commercial sales personnel worldwide. And we serve additional international markets through relationships with valued distributors. In all, our technologies are currently approved for use in more than 30 countries, and we continue to pursue regulatory approvals in more regions.